Analyst initiated coverage on Absci Corporation
$ABSI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Analyst initiated coverage of Absci Corporation with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2026 | $12.00 | Outperform | Leerink Partners |
| 5/28/2026 | $9.00 | Buy | BTIG Research |
| 1/8/2026 | $4.32 | Overweight → Equal-Weight | Morgan Stanley |
| 10/2/2025 | Overweight | Analyst | |
| 7/3/2025 | $7.00 | Overweight | Morgan Stanley |
| 1/22/2025 | $9.00 | Buy | Needham |
| 10/2/2024 | $10.00 | Buy | Guggenheim |
| 7/3/2024 | $7.00 | Overweight | Morgan Stanley |
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
4/A - Absci Corp (0001672688) (Issuer)
Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. T
A wave of government funding, hardware progress, and looming encryption deadlines has turned quantum from a lab curiosity into one of the most closely watched corners of the market in 2026, spanning computing hardware and the cybersecurity built to survive it.VANCOUVER, BC, July 6, 2026 /CNW/ -- USA News Group News Commentary, For years, quantum computing lived mostly in research papers and conference keynotes. In 2026 it has become something harder to ignore: a sector with federal capital behind it, a string of technical milestones on the board, and a parallel race to rebuild the world's encryption before quantum machines can break it. The result is one of the most polarizing themes in the
Leerink Partners initiated coverage of Absci Corporation with a rating of Outperform and set a new price target of $12.00
BTIG Research initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00
Morgan Stanley downgraded Absci Corporation from Overweight to Equal-Weight and set a new price target of $4.32
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
8-K - Absci Corp (0001672688) (Filer)
424B5 - Absci Corp (0001672688) (Filer)
8-K - Absci Corp (0001672688) (Filer)
Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. T
Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the
Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually
MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ:ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, "Partnering to Power the New Era of Drug Discovery," will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discover
Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat
SC 13G - Absci Corp (0001672688) (Subject)
SC 13G/A - Absci Corp (0001672688) (Subject)
SC 13D/A - Absci Corp (0001672688) (Subject)